Alternatives to mifepristone for early medical abortion.
نویسندگان
چکیده
OBJECTIVE To review published reports of first-trimester medical abortion regimens that do not include mifepristone. METHODS Reports listed in Pubmed and Medline on prospective and controlled trials of the efficacy of misoprostol, alone or associated with methotrexate, for first-trimester abortion were analyzed if they included more than 100 participants and were published since 1990. RESULTS The efficacy of regimens using misoprostol alone ranged from 84% to 96%, and when misoprostol was used with methotrexate the efficacy ranged from 70% to 97%. Efficacy rates were influenced by follow-up interval. Treatment for infection, bleeding, and incomplete abortion were infrequent with both methods (0.3%-5%). CONCLUSION Alone or in combination with methotrexate, misoprostol is an efficacious alternative to mifepristone for the medical termination of pregnancy.
منابع مشابه
Mifepristone in South Australia -- the first 1343 tablets.
BACKGROUND Mifepristone has recently become available in Australia but its use is restricted. OBJECTIVE To describe the use of mifepristone in South Australia in the period 2009-2010 and to explore options that may become available to general practitioners. DISCUSSION Mifepristone has been added to regimens for early and second trimester abortions - both medical and surgical abortions. It h...
متن کاملDifferent Time Schedules of Mifepristone and Misoprostol in Second Trimester Medical Abortion: A Comparative Study
Background & aim: Recently, the use of mifepristone followed by misoprostol after 36-48 h has been demonstrated to be an effective and safe method for the second trimester medical abortion. However, this regimen entails long total abortion time, and consequently increases the financial burden and anxiety in the patients. We hypothesize that one day interval would be also effective and can be us...
متن کاملMifepristone for early medical abortion: experiences in France, Great Britain and Sweden.
In September 2000, the Food and Drug Administration (FDA) approved mifepristone (also known by the trade name Mifeprex or its original French name, RU-486) for use along with a prostaglandin for ending pregnancies up to 49 days from the onset of a woman's last menstrual period. The FDA-approved protocol involves the administration of 600 mg of mifepristone followed two days later by 400 mg of o...
متن کاملA prospective randomized, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy
A prospective randomized, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Author: Dr Roopa Malik, Assistant Professor, Obstetrics and gynaecology department Pt BDS PGIMS Rohtak. Background: Vaginal misoprostol has been shown to be an effective single agent for medical agent for medical abortion. Th...
متن کاملMedical abortion with mifepristone and misoprostol: a clinical trial in Taiwanese women.
BACKGROUND AND PURPOSE Medical abortion was not officially approved in Taiwan until the end of 2001. We investigated the efficacy of combination mifepristone and misoprostol therapy for medical abortion (which has now been approved) in early pregnant Taiwanese women and whether the attitudes of women who received this treatment affected the clinical outcome of medical abortion. METHODS Eighty...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
دوره 96 3 شماره
صفحات -
تاریخ انتشار 2007